We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Final Guidance for End-of-Phase-IIA Meetings
FDA Issues Final Guidance for End-of-Phase-IIA Meetings
September 25, 2009
FDA discussions with sponsors at the end-of-Phase-IIA meetings for drug clinical trials should help sponsors select dosing regimens for the next phase and design informative dose-response trials that incorporate the quantitative data the sponsor has accumulated, the agency says in a final guidance.